{"product_id":"radiofrequency-ablation-for-papillary-thyroid-cancer-a-comprehensive-guide-to-a-minimally-invasive-treatment-option","title":"Radiofrequency Ablation for Papillary Thyroid Cancer: A Comprehensive Guide to a Minimally Invasive Treatment Option","description":"\u003cp\u003ePapillary thyroid carcinoma (PTC), the most common form of thyroid cancer, has traditionally been treated with surgery, but that approach carries risks of scarring, nerve damage, and lifelong hormone replacement. This review article examines ultrasound-guided radiofrequency ablation (RFA) as a minimally invasive alternative that uses heat generated by high-frequency electrical current to destroy cancer cells without removing the thyroid gland. Across multiple studies involving hundreds of patients, RFA has demonstrated tumor volume reduction rates of 93.7% to 100%, complete tumor disappearance rates ranging from 16.7% to 100%, and very low recurrence rates, while causing fewer complications than surgery and offering shorter hospital stays, lower costs, and better post-treatment quality of life.\u003c\/p\u003e\n\n\u003ch1\u003eRadiofrequency Ablation for Papillary Thyroid Cancer: A Comprehensive Guide to a Minimally Invasive Treatment Option\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#introduction\"\u003eIntroduction: Understanding Papillary Thyroid Cancer\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#what-is-rfa\"\u003eWhat Is Radiofrequency Ablation and How Does It Work?\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#rfa-procedure\"\u003eThe RFA Procedure: Step by Step\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#measuring-success\"\u003eHow Doctors Evaluate RFA Success\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#rfa-ptmc\"\u003eRFA for Small Thyroid Cancers (Papillary Thyroid Microcarcinoma)\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#rfa-multifocal\"\u003eRFA for Multiple or Bilateral Tumors\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#rfa-large\"\u003eRFA for Larger Tumors (Over 1 cm)\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#rfa-recurrent\"\u003eRFA for Recurrent or Metastatic Cancer\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#future-directions\"\u003eFuture Directions in RFA Research\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eWhat This Review Could Not Prove\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#recommendations\"\u003eRecommendations for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eRFA is a minimally invasive alternative to surgery for low-risk papillary thyroid microcarcinoma, with high tumor volume reduction and low recurrence rates.\u003c\/li\u003e\n\u003cli\u003eFor single low-risk tumors 1 cm or smaller, studies report complete disappearance rates of 33.7%–100% and recurrence rates of 0%–4.5%.\u003c\/li\u003e\n\u003cli\u003eCompared with surgery, RFA causes fewer complications, shorter hospital stays, less bleeding, lower costs, and better postoperative quality of life.\u003c\/li\u003e\n\u003cli\u003eRFA is not recommended for aggressive subtypes such as tall cell, columnar cell, or hobnail variants; careful patient selection is essential.\u003c\/li\u003e\n\u003cli\u003eFor recurrent tumors in the central neck, RFA is most effective when tumors have not yet invaded the trachea, and nerve injury has been reported in up to 12% of cases.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"introduction\"\u003eIntroduction: Understanding Papillary Thyroid Cancer\u003c\/h2\u003e\n\n\u003cp\u003eThyroid cancer is the most common cancer of the endocrine system—the network of glands that produce hormones regulating metabolism, growth, and countless bodily functions. Among all thyroid cancers, \u003cstrong\u003epapillary thyroid carcinoma (PTC)\u003c\/strong\u003e accounts for approximately \u003cstrong\u003e80% of cases\u003c\/strong\u003e. The word \"papillary\" refers to the finger-like projections seen when the cancer cells are examined under a microscope.\u003c\/p\u003e\n\n\u003cp\u003eMost PTC tumors grow slowly and behave in an \"indolent\" manner, meaning they tend not to spread aggressively. As a result, the overall prognosis for patients with PTC is generally excellent. However, the standard treatment has historically been surgery, and that brings its own set of challenges.\u003c\/p\u003e\n\n\u003cp\u003eSurgery for PTC can lead to several complications, including permanent injury to the recurrent laryngeal nerve (the nerve that controls the vocal cords), hypoparathyroidism (underfunctioning of the parathyroid glands, which regulate calcium), visible scarring, and hypothyroidism (underactive thyroid) requiring lifelong thyroid hormone replacement therapy. These complications can persist for a lifetime and significantly reduce a patient's quality of life.\u003c\/p\u003e\n\n\u003cp\u003eTo avoid overtreating patients whose cancers would likely never cause harm, doctors have turned to \u003cstrong\u003eactive surveillance (AS)\u003c\/strong\u003e—a strategy of closely monitoring the cancer without immediate treatment. However, many patients find this approach stressful. Studies have shown that the decision to undergo delayed surgery during active surveillance is frequently driven by \u003cstrong\u003epatient anxiety about the possibility of tumor growth and metastasis\u003c\/strong\u003e (spread to other parts of the body).\u003c\/p\u003e\n\n\u003cp\u003eThis is where radiofrequency ablation (RFA) enters the picture. RFA is a minimally invasive technique that destroys cancer cells using heat, guided by real-time ultrasound imaging. This review article, published in the journal \u003cem\u003eUltrasonography\u003c\/em\u003e in March 2024, examines the current state of evidence for RFA in treating PTC, carefully analyzing its effectiveness, safety, and what the future may hold.\u003c\/p\u003e\n\n\u003ch2 id=\"what-is-rfa\"\u003eWhat Is Radiofrequency Ablation and How Does It Work?\u003c\/h2\u003e\n\n\u003cp\u003eRFA works on a straightforward principle: heat kills cancer cells. A specialized needle (called an electrode) is inserted directly into the tumor, and a \u003cstrong\u003ehigh-frequency alternating current—between 200 and 1,200 kHz\u003c\/strong\u003e—is passed through it. This creates an oscillating (rapidly alternating) electric field around the needle tip.\u003c\/p\u003e\n\n\u003cp\u003eInside the tissue, this electrical field causes polar macromolecules (large molecules with positive and negative ends) and charged ions to vibrate at very high speeds. This rapid vibration generates \u003cstrong\u003efrictional heat\u003c\/strong\u003e. Once the temperature in the tissue reaches \u003cstrong\u003e60°C (140°F)\u003c\/strong\u003e, the affected cells undergo coagulation necrosis—a process where cells are irreversibly damaged, their proteins denature, and the tissue essentially \"cooks.\" The dead tissue then shrinks in volume and is gradually absorbed by the body over time.\u003c\/p\u003e\n\n\u003cp\u003eRFA is one of several thermal ablation technologies available, including microwave ablation, laser ablation, and high-intensity focused ultrasound. However, RFA has become the \u003cstrong\u003emost widely adopted method\u003c\/strong\u003e for treating PTC, thanks to its proven track record and precision.\u003c\/p\u003e\n\n\u003ch2 id=\"rfa-procedure\"\u003eThe RFA Procedure: Step by Step\u003c\/h2\u003e\n\n\u003cp\u003eBefore undergoing RFA, patients typically go through a thorough evaluation. This includes:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eUltrasound examination\u003c\/strong\u003e to assess the tumor's size, location, ultrasound characteristics, and blood supply (vascularity)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eComputed tomography (CT) scans\u003c\/strong\u003e of the neck and chest to check for lymph node involvement or distant metastases\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFine-needle aspiration or core needle biopsy\u003c\/strong\u003e for cytopathological or histopathological analysis, including testing for the BRAFV600E gene mutation\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLaboratory tests\u003c\/strong\u003e to assess thyroid function and blood coagulation (clotting) ability\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eWhen it comes to the procedure itself, here is what patients can expect:\u003c\/p\u003e\n\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePositioning:\u003c\/strong\u003e The patient lies on their back (supine position) with the shoulders cushioned and the head tilted backward to fully expose the neck.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eUltrasound assessment:\u003c\/strong\u003e Multiple ultrasound sections are scanned to map the exact relationship between the tumor and nearby tissues.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAnesthesia:\u003c\/strong\u003e After routine disinfection, \u003cstrong\u003e1% lidocaine hydrochloride\u003c\/strong\u003e (a local anesthetic) is injected into the tissue under ultrasound guidance.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtective fluid barrier:\u003c\/strong\u003e A liquid—either normal saline, 5% glucose, or lidocaine—is injected into the natural spaces around the thyroid gland. This creates a \u003cstrong\u003e5 to 10-millimeter protective zone\u003c\/strong\u003e that temporarily separates the tumor from critical structures like the trachea (windpipe), common carotid artery, and recurrent laryngeal nerve, shielding them from thermal injury.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eElectrode placement:\u003c\/strong\u003e A safe puncture route is selected, and the electrode needle is positioned inside the tumor under real-time ultrasound guidance.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAblation:\u003c\/strong\u003e For larger tumors, doctors use the \u003cstrong\u003emoving-shot technique\u003c\/strong\u003e, which divides the tumor into multiple small ablation units and treats each one with edge-overlapping ablations, moving the heat source to protect nearby tissue. For small tumors, the electrode is inserted into the center and remains stationary throughout the procedure.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMonitoring:\u003c\/strong\u003e Throughout the ablation, heart rate, blood pressure, and oxygen saturation are closely monitored.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eThe duration of ablation, along with the power and energy settings, depends on the tumor's size and composition. For \u003cstrong\u003ebipolar electrodes\u003c\/strong\u003e, power is typically set between \u003cstrong\u003e3 and 5 watts\u003c\/strong\u003e, while other RFA modalities may use up to \u003cstrong\u003e20 watts\u003c\/strong\u003e. After the procedure, \u003cstrong\u003econtrast-enhanced ultrasound\u003c\/strong\u003e is performed immediately to assess the ablated area, which should extend \u003cstrong\u003e3 to 5 mm beyond the tumor edge\u003c\/strong\u003e to ensure a safe margin and confirm complete ablation. Patients are then monitored in the hospital for \u003cstrong\u003e1 to 2 hours\u003c\/strong\u003e, and any complications are evaluated based on clinical signs and symptoms.\u003c\/p\u003e\n\n\u003cp\u003eThe procedure differs slightly depending on whether the target is a primary tumor or a recurrent\/metastatic lymph node:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFor primary PTC:\u003c\/strong\u003e Doctors typically use the \u003cstrong\u003etrans-isthmic approach\u003c\/strong\u003e (entering through the narrow bridge of thyroid tissue connecting the two lobes). This allows stable electrode positioning, monitoring of the active tip's proximity to the recurrent laryngeal nerve, and prevention of heated material leaking into the area around the thyroid. The goal is a safe margin of \u003cstrong\u003egreater than 3 mm\u003c\/strong\u003e.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFor lymph nodes:\u003c\/strong\u003e The needle path is chosen based on the node's location, the protective fluid barrier is formed around the lymph node itself, and a \u003cstrong\u003efixed ablation technique\u003c\/strong\u003e is generally used since these lesions are typically smaller.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"measuring-success\"\u003eHow Doctors Evaluate RFA Success\u003c\/h2\u003e\n\n\u003cp\u003eResearchers evaluate RFA effectiveness using specific endpoints. The \u003cstrong\u003eprimary endpoint\u003c\/strong\u003e is the disease progression rate, which encompasses local recurrence (tumor returning at the same site), development of new tumors, lymph node metastasis, distant metastasis, or death due to PTC. The \u003cstrong\u003esecondary endpoints\u003c\/strong\u003e include changes in tumor size and volume, tumor disappearance, technical success, procedure duration, hospital stay length, hospitalization costs, and postoperative quality of life.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eTechnical success\u003c\/strong\u003e is defined as the complete absence of enhancement on contrast-enhanced ultrasound at the conclusion of the procedure—meaning no blood flow is detected in the ablated region, indicating the tumor tissue has been destroyed.\u003c\/p\u003e\n\n\u003cp\u003eSafety is assessed by tracking complications. \u003cstrong\u003eSerious complications\u003c\/strong\u003e include thermal injury to surrounding structures (major vessels, esophagus, trachea, brachial plexus, or sympathetic chain), significant hematoma formation (collections of blood outside blood vessels), and hemorrhage. The \u003cstrong\u003emost frequent complications\u003c\/strong\u003e are a sensation of heat during the procedure and pain or discomfort during or after treatment. Vocal changes due to thermal injury to the recurrent laryngeal nerve are another common and clinically significant complication that doctors watch for carefully.\u003c\/p\u003e\n\n\u003ch2 id=\"rfa-ptmc\"\u003eRFA for Small Thyroid Cancers (Papillary Thyroid Microcarcinoma)\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003ePapillary thyroid microcarcinoma (PTMC)\u003c\/strong\u003e is defined as a PTC tumor measuring \u003cstrong\u003e10 mm (1 cm) or less\u003c\/strong\u003e in diameter. The use of ultrasound-guided RFA for thyroid cancer was \u003cstrong\u003efirst reported by Dupuy et al. in 2001\u003c\/strong\u003e. Since then, more than two decades of research have produced numerous high-quality studies with large patient groups and extended follow-up periods.\u003c\/p\u003e\n\n\u003cp\u003eA recent review of the literature reported that RFA for low-risk PTMC yields:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\u003cstrong\u003eTumor volume reduction rates of 98.5% to 100%\u003c\/strong\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003cstrong\u003eComplete disappearance rates ranging from 33.7% to 100%\u003c\/strong\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003cstrong\u003eTumor progression or recurrence rates between 0% and 4.5%\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eTwo systematic reviews and meta-analyses, as well as a large-scale matching study, found \u003cstrong\u003eno significant differences in postoperative outcomes between RFA and surgery\u003c\/strong\u003e for single low-risk PTMC. These outcomes included local tumor progression, lymph node metastasis, salvage surgery (surgery performed after another treatment has failed), and recurrence-free survival. However, the \u003cstrong\u003erate of complications was significantly higher after surgery than after RFA\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eFurthermore, RFA proved significantly superior to surgery in terms of hospitalization costs, length of hospital stay, procedure duration, volume of bleeding, and postoperative quality of life. Importantly, RFA does not negatively impact subsequent surgical treatments if they become necessary later.\u003c\/p\u003e\n\n\u003cp\u003eThe table below summarizes key studies on RFA for single low-risk PTMC:\u003c\/p\u003e\n\n\u003ctable border=\"1\" cellpadding=\"5\" cellspacing=\"0\"\u003e\n  \u003ctr\u003e\n    \u003cth\u003eStudy\u003c\/th\u003e\n    \u003cth\u003eCountry\u003c\/th\u003e\n    \u003cth\u003eResearch Perspective\u003c\/th\u003e\n    \u003cth\u003eFollow-up (months)\u003c\/th\u003e\n    \u003cth\u003ePatients\u003c\/th\u003e\n    \u003cth\u003eVolume Reduction\u003c\/th\u003e\n    \u003cth\u003eComplete Disappearance\u003c\/th\u003e\n    \u003cth\u003eRecurrence\u003c\/th\u003e\n    \u003cth\u003eAdverse Reactions\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eSong et al. (2020)\u003c\/td\u003e\n    \u003ctd\u003eChina\u003c\/td\u003e\n    \u003ctd\u003eLarge sample\u003c\/td\u003e\n    \u003ctd\u003e30.2 ± 13.9\u003c\/td\u003e\n    \u003ctd\u003e112\u003c\/td\u003e\n    \u003ctd\u003e100%\u003c\/td\u003e\n    \u003ctd\u003e100%\u003c\/td\u003e\n    \u003ctd\u003e0\u003c\/td\u003e\n    \u003ctd\u003e1\/112 (0.9%)\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eYan et al. (2021)\u003c\/td\u003e\n    \u003ctd\u003eChina\u003c\/td\u003e\n    \u003ctd\u003eLarge sample\u003c\/td\u003e\n    \u003ctd\u003e42.1 ± 11.9\u003c\/td\u003e\n    \u003ctd\u003e414\u003c\/td\u003e\n    \u003ctd\u003e98.8%\u003c\/td\u003e\n    \u003ctd\u003e88.4%\u003c\/td\u003e\n    \u003ctd\u003e0\u003c\/td\u003e\n    \u003ctd\u003e10\/414 (2.4%)\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eZhang et al. (2016)\u003c\/td\u003e\n    \u003ctd\u003eChina\u003c\/td\u003e\n    \u003ctd\u003eLong-term follow-up\u003c\/td\u003e\n    \u003ctd\u003e64.2 ± 2.8\u003c\/td\u003e\n    \u003ctd\u003e92\u003c\/td\u003e\n    \u003ctd\u003eNot reported\u003c\/td\u003e\n    \u003ctd\u003eNot reported\u003c\/td\u003e\n    \u003ctd\u003e0\u003c\/td\u003e\n    \u003ctd\u003e1\/92 (1.1%)\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eSeo et al. (2021)\u003c\/td\u003e\n    \u003ctd\u003eKorea\u003c\/td\u003e\n    \u003ctd\u003eLong-term follow-up\u003c\/td\u003e\n    \u003ctd\u003e130.6 (range 121–159)\u003c\/td\u003e\n    \u003ctd\u003e5\u003c\/td\u003e\n    \u003ctd\u003eNot reported\u003c\/td\u003e\n    \u003ctd\u003e60%\u003c\/td\u003e\n    \u003ctd\u003e0\u003c\/td\u003e\n    \u003ctd\u003e0\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThese studies confirm that RFA is a safe and effective treatment for single low-risk PTMC—cases without evidence of extrathyroidal extension (spread beyond the thyroid), lymph node metastasis, distant metastasis, or aggressive histological subtypes. Compared with surgery, RFA may offer a more cost-effective alternative for patients with PTMC who cannot or choose not to undergo surgery or active surveillance.\u003c\/p\u003e\n\n\u003ch2 id=\"rfa-multifocal\"\u003eRFA for Multiple or Bilateral Tumors\u003c\/h2\u003e\n\n\u003cp\u003eCurrent guidelines only officially recommend thermal ablation for \u003cstrong\u003esingle\u003c\/strong\u003e low-risk PTMC. However, a growing body of research has examined whether RFA can also work for patients with multiple tumors or tumors in both lobes of the thyroid (bilateral disease).\u003c\/p\u003e\n\n\u003cp\u003eThree studies from China have produced encouraging results:\u003c\/p\u003e\n\n\u003ctable border=\"1\" cellpadding=\"5\" cellspacing=\"0\"\u003e\n  \u003ctr\u003e\n    \u003cth\u003eStudy\u003c\/th\u003e\n    \u003cth\u003eType\u003c\/th\u003e\n    \u003cth\u003eFollow-up (months)\u003c\/th\u003e\n    \u003cth\u003ePatients\u003c\/th\u003e\n    \u003cth\u003eVolume Reduction\u003c\/th\u003e\n    \u003cth\u003eComplete Disappearance\u003c\/th\u003e\n    \u003cth\u003eRecurrence\u003c\/th\u003e\n    \u003cth\u003eAdverse Reactions\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eYan et al. (2021)\u003c\/td\u003e\n    \u003ctd\u003eBilateral PTMCs\u003c\/td\u003e\n    \u003ctd\u003e44.8 ± 11.5\u003c\/td\u003e\n    \u003ctd\u003e47\u003c\/td\u003e\n    \u003ctd\u003e99.9%\u003c\/td\u003e\n    \u003ctd\u003e92.0%\u003c\/td\u003e\n    \u003ctd\u003e0\u003c\/td\u003e\n    \u003ctd\u003eLocalized pain 2\/47 (4.3%); PTMC 4\/47 (8.5%)\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eYan et al. (2022)\u003c\/td\u003e\n    \u003ctd\u003eMultifocal PTMCs\u003c\/td\u003e\n    \u003ctd\u003e47.9 ± 11.4\u003c\/td\u003e\n    \u003ctd\u003e55\u003c\/td\u003e\n    \u003ctd\u003e99.9%\u003c\/td\u003e\n    \u003ctd\u003e95.6%\u003c\/td\u003e\n    \u003ctd\u003e0\u003c\/td\u003e\n    \u003ctd\u003eLocalized pain 1\/55 (1.8%); PTMC 3\/55 (5.4%)\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eYan et al. (2023)\u003c\/td\u003e\n    \u003ctd\u003eMultifocal PTMCs\u003c\/td\u003e\n    \u003ctd\u003e72.9\u003c\/td\u003e\n    \u003ctd\u003e44\u003c\/td\u003e\n    \u003ctd\u003eNot reported\u003c\/td\u003e\n    \u003ctd\u003e95.5%\u003c\/td\u003e\n    \u003ctd\u003e0\u003c\/td\u003e\n    \u003ctd\u003eLN metastasis 1\/44 (2.3%); persistent lesion 1\/44 (2.3%)\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eWhile these results are promising, the sample sizes in these studies were relatively small. The authors emphasize that \u003cstrong\u003elarge-scale research with long-term follow-up periods is still needed\u003c\/strong\u003e to confirm the safety and effectiveness of RFA for bilateral and multifocal PTMC.\u003c\/p\u003e\n\n\u003ch2 id=\"rfa-large\"\u003eRFA for Larger Tumors (Over 1 cm)\u003c\/h2\u003e\n\n\u003cp\u003eFor patients with larger PTC tumors that have not spread to lymph nodes—specifically those classified as \u003cstrong\u003eT1bN0M0\u003c\/strong\u003e (tumors larger than 1 cm but not exceeding 2 cm, with no lymph node involvement or distant metastasis) or \u003cstrong\u003eT2N0M0\u003c\/strong\u003e (tumors larger than 2 cm but not exceeding 4 cm, with no spread)—the 2015 American Thyroid Association guidelines recommend lobectomy with isthmic resection (removing only the affected lobe and the connecting bridge of tissue) rather than total thyroidectomy. This shift in guidelines reflects a growing preference for \u003cstrong\u003econservative treatment\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eRecent research indicates that RFA for these larger tumors may produce outcomes comparable to those seen in T1aN0M0 tumors (the smallest category, 1 cm or less). The authors suggest this could be because PTC generally behaves in an indolent manner, and T1a, T1b, and T2 tumors have similar prognoses. The key studies are summarized below:\u003c\/p\u003e\n\n\u003ctable border=\"1\" cellpadding=\"5\" cellspacing=\"0\"\u003e\n  \u003ctr\u003e\n    \u003cth\u003eStudy\u003c\/th\u003e\n    \u003cth\u003eTumor Type\u003c\/th\u003e\n    \u003cth\u003eFollow-up (months)\u003c\/th\u003e\n    \u003cth\u003ePatients\u003c\/th\u003e\n    \u003cth\u003eVolume Reduction\u003c\/th\u003e\n    \u003cth\u003eComplete Disappearance\u003c\/th\u003e\n    \u003cth\u003eRecurrence\u003c\/th\u003e\n    \u003cth\u003eAdverse Reactions\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eXiao et al. (2021)\u003c\/td\u003e\n    \u003ctd\u003eT1bN0M0\u003c\/td\u003e\n    \u003ctd\u003e26 ± 10.3\u003c\/td\u003e\n    \u003ctd\u003e91\u003c\/td\u003e\n    \u003ctd\u003e99.0%\u003c\/td\u003e\n    \u003ctd\u003eNot reported\u003c\/td\u003e\n    \u003ctd\u003e0\u003c\/td\u003e\n    \u003ctd\u003eLocalized pain 3\/91 (3.3%); PTMC 2\/91 (2.2%)\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eHe et al. (2021)\u003c\/td\u003e\n    \u003ctd\u003eT1bN0M0\u003c\/td\u003e\n    \u003ctd\u003e36\u003c\/td\u003e\n    \u003ctd\u003e94\u003c\/td\u003e\n    \u003ctd\u003e99.9%\u003c\/td\u003e\n    \u003ctd\u003eNot reported\u003c\/td\u003e\n    \u003ctd\u003e0\u003c\/td\u003e\n    \u003ctd\u003eModerate fever 4\/94 (4.3%); hoarseness 1\/94 (1.1%); PTMC 1\/94 (1.1%)\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eYan et al. (2023)\u003c\/td\u003e\n    \u003ctd\u003eT1bN0M0\u003c\/td\u003e\n    \u003ctd\u003e50.4\u003c\/td\u003e\n    \u003ctd\u003e91\u003c\/td\u003e\n    \u003ctd\u003eNot reported\u003c\/td\u003e\n    \u003ctd\u003e74.7%\u003c\/td\u003e\n    \u003ctd\u003e0\u003c\/td\u003e\n    \u003ctd\u003ePTMC 2\/91 (2.2%)\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eXiao et al. (2021)\u003c\/td\u003e\n    \u003ctd\u003eT2N0M0\u003c\/td\u003e\n    \u003ctd\u003e24.1 ± 6.9\u003c\/td\u003e\n    \u003ctd\u003e12\u003c\/td\u003e\n    \u003ctd\u003e93.7%\u003c\/td\u003e\n    \u003ctd\u003e16.7%\u003c\/td\u003e\n    \u003ctd\u003e0\u003c\/td\u003e\n    \u003ctd\u003e0\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eBased on these findings, RFA may be a \u003cstrong\u003eviable alternative treatment option\u003c\/strong\u003e for patients with larger PTCs who are not good candidates for surgery or who prefer to avoid it.\u003c\/p\u003e\n\n\u003ch2 id=\"rfa-recurrent\"\u003eRFA for Recurrent or Metastatic Cancer\u003c\/h2\u003e\n\n\u003cp\u003eStudies show that between \u003cstrong\u003e10.0% and 30.0%\u003c\/strong\u003e of patients with highly differentiated thyroid cancer experience local recurrence (the cancer returning in the neck) or metastasis (spread to other areas) after surgical treatment. Reoperating on these patients is challenging because anatomical changes and fibrosis (scarring) from the initial surgery can make reoperation difficult and risky. For this reason, current guidelines advocate the use of thermal ablation for the \u003cstrong\u003eradical (curative) or palliative (symptom-relieving) treatment\u003c\/strong\u003e of recurrent or metastatic PTC.\u003c\/p\u003e\n\n\u003ch3\u003eCurative Ablation for Locally Recurrent Thyroid Cancer\u003c\/h3\u003e\n\n\u003cp\u003eThe European 2021 guidelines state that radical ablation is feasible when there are \u003cstrong\u003ethree or fewer recurrent PTC tumors in the neck, each with a diameter of less than 2 cm\u003c\/strong\u003e, and no distant metastasis. A meta-analysis evaluating RFA for locally recurrent and metastatic PTCs reported:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\u003cstrong\u003eTumor volume reduction rate: 89.5% to 100%\u003c\/strong\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003cstrong\u003eComplete disappearance rate: 68.8%\u003c\/strong\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003cstrong\u003eAverage of only 1.3 ablation sessions required\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eKim et al. found \u003cstrong\u003eno significant differences in 3-year recurrence-free survival rates\u003c\/strong\u003e between RFA and reoperation for locally recurrent PTCs smaller than 2 cm. A recent meta-analysis confirmed that thermal ablation is safe and effective for locally recurrent and metastatic PTCs. However, \u003cstrong\u003emajor complications, such as nerve injury, have been reported in up to 12% of cases\u003c\/strong\u003e, particularly when the recurrent tumors are located in the central neck region. The authors advise caution before proceeding with ablation of recurrent tumors in this area.\u003c\/p\u003e\n\n\u003cp\u003eMonitoring the biochemical response after RFA is also critical. \u003cstrong\u003eSerum thyroglobulin (Tg) levels\u003c\/strong\u003e—a protein produced by thyroid cells—are a sensitive marker for predicting recurrence and metastasis. Tg levels can serve as an effective indicator of whether ablation was successful. Doctors also account for \u003cstrong\u003eanti-Tg antibodies\u003c\/strong\u003e, which can temporarily rise after surgery as part of the immune response and may cause underestimation of serum Tg levels in standard tests.\u003c\/p\u003e\n\n\u003ch3\u003ePalliative Ablation for Recurrent Thyroid Cancer\u003c\/h3\u003e\n\n\u003cp\u003eWhen recurrent metastatic thyroid cancer invades critical structures or causes cosmetic concerns, reducing tumor volume becomes essential to relieve symptoms and improve quality of life. The American Thyroid Association recommends several management strategies for these cases, including reoperation, active surveillance, iodine-131 therapy (for disease responsive to radioactive iodine), external beam radiation therapy, and other nonsurgical approaches. \u003cstrong\u003ePalliative RFA is one such approach.\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cp\u003eChung et al. studied RFA for recurrent thyroid cancer in the central neck area after surgery, categorizing tumors by their spatial relationship to the trachea. Their findings were striking:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eTumors \u003cstrong\u003ewithout tracheal invasion\u003c\/strong\u003e had the \u003cstrong\u003ehighest complete disappearance rate at 85.0%\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003eThe rate decreased progressively for tumors forming acute, right, and obtuse angles with the trachea\u003c\/li\u003e\n  \u003cli\u003eThe \u003cstrong\u003elowest rate\u003c\/strong\u003e was seen in cases of intraluminal tracheal infiltration (tumor growing into the windpipe's interior)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe study reported a relatively high \u003cstrong\u003etotal complication rate of 21.4%\u003c\/strong\u003e, likely due to the inclusion of tumors located close to critical neck structures. Nevertheless, \u003cstrong\u003eno life-threatening complications or long-term sequelae\u003c\/strong\u003e occurred during the follow-up period. Because RFA effectiveness is inversely related to the extent of tracheal invasion, the authors advise \u003cstrong\u003eearly RFA treatment\u003c\/strong\u003e for recurrent tumors in the central neck region.\u003c\/p\u003e\n\n\u003cp\u003eFor especially challenging cases—including lesions protruding from the skin or those that have ruptured—ultrasound-guided RFA combined with \u003cstrong\u003eiodine-125 seed implantation\u003c\/strong\u003e has proven effective. Zhai et al. found that this combination approach safely and effectively controlled local metastatic tumors while also \u003cstrong\u003eimproving patients' quality of life\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch2 id=\"future-directions\"\u003eFuture Directions in RFA Research\u003c\/h2\u003e\n\n\u003cp\u003eWhile multiple studies have confirmed the safety and effectiveness of RFA for PTC, the review's authors identify three key areas where additional research is needed.\u003c\/p\u003e\n\n\u003ch3\u003eImproving Detection of Occult Cervical Lymph Node Metastasis\u003c\/h3\u003e\n\n\u003cp\u003eMetastasis to cervical (neck) lymph nodes is common in PTC, but detecting small metastatic lymph nodes on ultrasound is challenging. Several clinical studies suggest that \u003cstrong\u003econtrast-enhanced ultrasound\u003c\/strong\u003e may help. Xiao et al. found that the \u003cstrong\u003eisoenhancement pattern on post-vascular contrast-enhanced ultrasound with perfluorobutane\u003c\/strong\u003e (a contrast agent) was effective in identifying small cervical lymph nodes (short axis diameter of 8 mm or less) suspected of containing PTC. Zhang et al. reported that \u003cstrong\u003econtrast-enhanced ultrasound lymphography\u003c\/strong\u003e provided better diagnostic performance than conventional B-mode ultrasound, especially for lymph node metastases smaller than 1 cm and for central cervical lymph node metastases. This technology could represent a new approach for early detection of lymph node spread.\u003c\/p\u003e\n\n\u003ch3\u003eAccurately Assessing PTC Aggressiveness\u003c\/h3\u003e\n\n\u003cp\u003ePTC is not a single disease—it includes \u003cstrong\u003e13 histopathological subtypes\u003c\/strong\u003e. The most aggressive of these are the \u003cstrong\u003etall cell, columnar cell, and hobnail variants\u003c\/strong\u003e, which have unique clinical, pathological, and molecular characteristics. RFA is \u003cstrong\u003enot recommended\u003c\/strong\u003e for these aggressive subtypes. Preoperative assessment of tumor aggressiveness is therefore essential for tailoring treatment appropriately.\u003c\/p\u003e\n\n\u003cp\u003eThe authors suggest that combining analysis of \u003cstrong\u003emolecular markers\u003c\/strong\u003e—such as the BRAF, RAS, TERT promoter, RET, and TP53 genes, along with the fusion genes RET\/PTC, PAX8\/PPARG, and NTRK—with \u003cstrong\u003eartificial intelligence\u003c\/strong\u003e may enable more accurate evaluation of PTC aggressiveness, prognosis, and recurrence risk in the future.\u003c\/p\u003e\n\n\u003ch3\u003eNew Technologies for Minimally Invasive Therapy\u003c\/h3\u003e\n\n\u003cp\u003eThe thyroid gland sits in a crowded anatomical neighborhood, surrounded by the carotid artery, trachea, esophagus, and nerves. This proximity increases the risk of thermal damage during RFA. One promising new approach is \u003cstrong\u003eirreversible electroporation\u003c\/strong\u003e, which uses high-voltage direct current to create a strong electric field. This induces the formation of \u003cstrong\u003epermanent nanoscale fissures (tiny holes) in the cell membrane\u003c\/strong\u003e, leading to apoptosis (programmed cell death) and tumor necrosis.\u003c\/p\u003e\n\n\u003cp\u003eUnlike thermal ablation, irreversible electroporation \u003cstrong\u003edoes not generate heat\u003c\/strong\u003e, so it preserves tissues that lack cellular components, such as blood vessels and nerves. Clinical studies have already confirmed its usefulness for liver and pancreatic cancers, suggesting it may become a viable ablation option for thyroid cancer as well—potentially with \u003cstrong\u003efewer complications than surgery\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eAdditionally, researchers are working on improving ultrasound visualization, since ultrasound cannot penetrate bone tissue, which can compromise clear imaging of target lesions in some cases.\u003c\/p\u003e\n\n\u003ch2 id=\"limitations\"\u003eWhat This Review Could Not Prove\u003c\/h2\u003e\n\n\u003cp\u003eThe authors acknowledge several important limitations. First, \u003cstrong\u003emost large-scale studies on RFA for PTC have been conducted in Asia\u003c\/strong\u003e (primarily China and Korea), with relatively few investigations carried out in Western countries. This geographic concentration may affect how broadly the findings can be generalized to other populations.\u003c\/p\u003e\n\n\u003cp\u003eSecond, studies on \u003cstrong\u003ebilateral and multifocal PTMC\u003c\/strong\u003e have relatively small sample sizes, and long-term follow-up data are still needed to confirm safety and effectiveness for these indications. Third, while RFA appears to be very effective for low-risk tumors, data on its use in more aggressive PTC subtypes remain limited, and it is explicitly not recommended for the most aggressive variants.\u003c\/p\u003e\n\n\u003cp\u003eFinally, the review notes that major complications, particularly nerve injury, have been reported in up to 12% of cases when treating recurrent tumors in the central neck—a reminder that RFA is not entirely risk-free and patient selection matters greatly.\u003c\/p\u003e\n\n\u003ch2 id=\"recommendations\"\u003eRecommendations for Patients\u003c\/h2\u003e\n\n\u003cp\u003eBased on the evidence presented in this review, here is what patients should know when discussing treatment options with their healthcare team:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRFA is a proven option for low-risk PTC.\u003c\/strong\u003e For patients with single low-risk papillary thyroid microcarcinoma (tumors 1 cm or less) who are ineligible for or decline surgery and active surveillance, RFA offers tumor volume reduction rates of 98.5% to 100%, complete disappearance rates of 33.7% to 100%, and recurrence rates of only 0% to 4.5%.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRFA is safer than surgery in key respects.\u003c\/strong\u003e It causes fewer complications, shorter hospital stays, less bleeding, lower costs, and better postoperative quality of life—and it does not rule out future surgery if needed.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRFA is expanding to more complex cases.\u003c\/strong\u003e Emerging evidence supports its use for bilateral and multifocal tumors, larger tumors (up to T2N0M0), and recurrent or metastatic disease, though more research is needed for these indications.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNot all PTCs are treatable with RFA.\u003c\/strong\u003e The most aggressive subtypes (tall cell, columnar cell, and hobnail variants) should not be treated with RFA. A thorough pre-treatment evaluation—including ultrasound, CT, biopsy, genetic testing for BRAFV600E, and laboratory tests—is essential.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eEarly treatment of recurrent tumors matters.\u003c\/strong\u003e For recurrent cancer in the central neck, RFA is most effective when tumors have not yet invaded the trachea. Patients with recurrent disease should discuss RFA options promptly rather than waiting.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eAs with any medical decision, patients should have a \u003cstrong\u003emultidisciplinary consultation\u003c\/strong\u003e whenever possible, involving surgeons, endocrinologists, radiologists, and other specialists to determine the most appropriate treatment plan for their individual situation.\u003c\/p\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWhat is radiofrequency ablation (RFA) for papillary thyroid cancer?\u003c\/h3\u003e\n\u003cp\u003eRFA is a minimally invasive treatment that uses heat from high-frequency electrical current to destroy cancer cells without removing the thyroid gland. A needle electrode is placed into the tumor under ultrasound guidance, heating tissue above 60°C to cause cell death. It is an alternative to surgery or active surveillance for certain patients.\u003c\/p\u003e\n\u003ch3\u003eWho is a candidate for RFA of papillary thyroid cancer?\u003c\/h3\u003e\n\u003cp\u003eRFA is a proven option for single low-risk papillary thyroid microcarcinoma, meaning a tumor 1 cm or smaller with no spread beyond the thyroid or to lymph nodes. It is not recommended for aggressive subtypes such as tall cell, columnar cell, or hobnail variants. Patients must have a thorough evaluation before treatment.\u003c\/p\u003e\n\u003ch3\u003eWhat side effects or complications can occur with RFA?\u003c\/h3\u003e\n\u003cp\u003eThe most frequent side effects are a sensation of heat and pain during or after treatment. Vocal changes from nerve injury can occur. Serious complications, such as injury to surrounding structures or significant bleeding, are possible but less common than with surgery. For recurrent tumors in the central neck, nerve injury has been reported in up to 12% of cases.\u003c\/p\u003e\n\u003ch3\u003eWhat happens during the RFA procedure?\u003c\/h3\u003e\n\u003cp\u003eYou lie on your back with your neck exposed. After local anesthesia, doctors inject fluid around the thyroid to create a protective barrier for nearby structures. An electrode is placed into the tumor under ultrasound guidance. For larger tumors, multiple overlapping ablations are performed. Afterward, you are monitored for 1 to 2 hours.\u003c\/p\u003e\n\u003ch3\u003eCan RFA be used for larger thyroid cancers or multiple tumors?\u003c\/h3\u003e\n\u003cp\u003eEmerging evidence shows RFA may work for tumors larger than 1 cm and for multiple or bilateral tumors, but studies are smaller and less conclusive. For example, one study of T2N0M0 tumors found a 93.7% volume reduction. Larger tumors up to T2N0M0 have shown promising results, but more research is needed.\u003c\/p\u003e\n\u003ch3\u003eDoes RFA prevent the need for future surgery if cancer recurs?\u003c\/h3\u003e\n\u003cp\u003eRFA does not negatively impact subsequent surgical treatments if they become necessary later. Studies show that RFA for low-risk papillary thyroid microcarcinoma has low recurrence rates, and if surgery is needed later, it can still be performed. However, RFA is not entirely risk-free and patient selection is important.\u003c\/p\u003e\n\u003ch3\u003eMy doctor recommends surgery for papillary thyroid microcarcinoma, but I read about radiofrequency ablation (RFA). Should I get a second opinion before deciding between RFA and surgery?\u003c\/h3\u003e\n\u003cp\u003eFor a single low-risk papillary thyroid microcarcinoma (1 cm or less), radiofrequency ablation (RFA) has shown tumor volume reduction rates of 98.5–100%, complete disappearance in 33.7–100% of cases, and recurrence of only 0–4.5%. RFA causes fewer complications than surgery, with shorter hospital stays, lower costs, and better post-treatment quality of life, and it does not prevent later surgery if needed. However, aggressive histologic subtypes should not be treated with RFA. A second opinion can clarify whether your tumor is truly low-risk and whether RFA, surgery, or active surveillance fits your situation. Diagnostic Detectives Network provides independent expert second opinions.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eOriginal Article:\u003c\/strong\u003e \"Ultrasound-guided radiofrequency ablation for the treatment of papillary thyroid carcinoma: a review of the current state and future perspectives\"\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAuthors:\u003c\/strong\u003e Guo-zheng Zhao and Ming-bo Zhang\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePublication:\u003c\/strong\u003e \u003cem\u003eUltrasonography\u003c\/em\u003e 2024; 43:79-87 (https:\/\/doi.org\/10.14366\/usg.23091)\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAffiliations:\u003c\/strong\u003e Department of Ultrasound, First Medical Center, Chinese PLA General Hospital, Beijing, China; Department of Ultrasound, Air Force Medical Center, Beijing, China\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eReceived:\u003c\/strong\u003e May 15, 2023 | \u003cstrong\u003eRevised:\u003c\/strong\u003e December 1, 2023 | \u003cstrong\u003eAccepted:\u003c\/strong\u003e December 11, 2023\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eKeywords:\u003c\/strong\u003e Thyroid; Papillary carcinoma; Ultrasound; Radiofrequency ablation\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eNote:\u003c\/strong\u003e This patient-friendly article is based on peer-reviewed research published in an open-access medical journal. It is intended for educational purposes and does not constitute medical advice. Patients should consult their healthcare providers for guidance on their specific condition. The original article is distributed under the Creative Commons Attribution Non-Commercial License (CC BY-NC 4.0).\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47541991899292,"sku":null,"price":0.0,"currency_code":"KRW","in_stock":true}],"url":"https:\/\/diagnosticdetectives.kr\/products\/radiofrequency-ablation-for-papillary-thyroid-cancer-a-comprehensive-guide-to-a-minimally-invasive-treatment-option","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}